drugset
drugset / Trial / NCT07664150

CW-301 FIH Study of CAN016

NCT07664150 ↗

Phase 1/2 Recruiting 90 enrolled Canwell Biotech Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients with Advanced Solid Tumors

Timeline

Start
2026-06-18
Primary completion
2028-12-30
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CAN016 Unknown 0.75 mg/kg Intravenous

Indications

No indication recorded.